Biblio Discovery — Demo Discovery Service

12 results for "Shreyaskumar Patel"

Showing 1–12 · 2.73 seconds · RSS

  1. Journal Article

    An adaptive transformer-based framework for advanced brain activity mapping and intelligent neurotherapeutic decision support

    Bhushankumar Nemade; Vikram Kulkarni; Deven Shah et al.

    Frontiers in Human Neuroscience, Vol. 19 · 2025 · English · DOAJ Scopus

    IntroductionIdentification and treatment of neurological disorders depend much on brain imaging and neurotherapeutic decision support. Although they are loud, do not remain in one spot, and are rather complex, electroencephalogram (EEG) signals are the principal tool used in research of brain…

  2. Journal Article Full text

    Molecular Imaging with 3′-deoxy-3′[(18)F]-Fluorothymidine (18F-FLT) PET/CT for Early Response to Targeted Therapies in Sarcomas: A Pilot Study

    Kalevi Kairemo; Elmer B. Santos; Homer A. Macapinlac et al.

    Diagnostics, Vol. 10 No. 3 · 2020 · English · DOAJ Scopus

    Although 3′-deoxy-3′[(18)F]-fluorothymidine (FLT)-positron emission tomography (PET) has been utilized for tumor response assessment to neoadjuvant chemotherapy in soft tissue sarcomas, it has not been exploited for the assessment of early response to systematically targeted therapies. Herein, we…

  3. Journal Article

    Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials

    Roman Groisberg; David S. Hong; Amini Behrang et al.

    Journal for ImmunoTherapy of Cancer, Vol. 5 No. 1 · 2017 · English · DOAJ Scopus

    Abstract Background Immunotherapies, specifically those based on immune checkpoint inhibitors, have shown promising activity in multiple tumor types. Other than mifamurtide (MEPACT®) for osteosarcoma approved by European Medicines Agency, there are no approved immunotherapies for sarcomas. Methods…

  4. Journal Article

    Systematic Review of Surgical Treatment Outcomes of Prostate Metastases to the Spine

    Michelle Clarke; Camilo Molina; Daryl Fourney et al.

    Global Spine Journal, Vol. 5 · 2015 · English · DOAJ Scopus

    Introduction Treatment of symptomatic spinal metastases through surgical decompression and reconstruction is known to improve quality of life in patients with cancer. However, most studies have been performed on patients with mixed tumor histopathology. We systematically review the literature for…

  5. Journal Article

    A Systematic Review of Clinical Outcomes and Prognostic Factors for Patients Undergoing Surgery for Spinal Metastases Secondary to Breast Cancer

    Daniel Sciubba; Alp Yurter; Derek Ju et al.

    Global Spine Journal, Vol. 5 · 2015 · English · DOAJ Scopus

    Introduction Surgical treatment and cement augmentation procedures are effective palliative techniques for the treatment of symptomatic spinal metastases. However, clinical results specific to a breast cancer cohort are generally lacking. We aim to systematically review the literature for clinical…

  6. Journal Article

    Retrospective evaluation of the role of gemcitabine‐docetaxel in well‐differentiated and dedifferentiated liposarcoma

    Prapassorn Thirasastr; Heather Lin; Behrang Amini et al.

    Cancer Medicine, Vol. 12 No. 4 · 2023 · English · DOAJ Scopus

    Abstract Objective Well‐differentiated (WDLPS) and dedifferentiated liposarcoma (DDLPS) account for the majority of liposarcomas. Although gemcitabine‐docetaxel is used as second‐line treatment in soft tissue sarcomas, its efficacy in WDLPS/DDLPS is not established. This study retrospectively…

  7. Journal Article

    Immuno-genomic landscape of osteosarcoma

    Chia-Chin Wu; Hannah C. Beird; J. Andrew Livingston et al.

    Nature Communications, Vol. 11 No. 1 · 2020 · English · DOAJ Scopus

    The efficacy of immune checkpoint inhibitors (ICI) in osteosarcoma has been limited. Here, the authors investigate the immunogenomic landscape of osteosarcoma, and integrated analyses highlight features related to a suppressed immune microenvironment.

  8. Journal Article

    AO Spine Clinical Practice Recommendations: Current Systemic Oncological Treatments with the Largest Impact on Patients with Metastatic Spinal Disease

    Marcin Czyz MD, PhD; Emerens G. Wensink MD, PhD; Brian Coimbra MD et al.

    Global Spine Journal, Vol. 15 · 2025 · English · DOAJ Scopus

    Study Design Literature review with clinical recommendation. Objective To provide the readers with a concise curation of the latest literature in recent advances in systemic oncological therapies and their implications for decision-making in patients with metastatic spinal disease. This review aims…

  9. Journal Article

    Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma

    Sandra P. D’Angelo; Allison L. Richards; Anthony P. Conley et al.

    Nature Communications, Vol. 13 No. 1 · 2022 · English · DOAJ Scopus

    The activity of PD-1 blockade in patients with sarcoma has been modest so far. Here, the authors report the results of a pilot clinical trial to assess the efficacy and safety of bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, in combination with the PD1 blockade…

  10. Journal Article

    Dedifferentiated liposarcomas treated with immune checkpoint blockade: the MD Anderson experience

    Madeline B. Torres; Cheuk Hong Leung; Marianne Zoghbi et al.

    Frontiers in Immunology, Vol. 16 · 2025 · English · DOAJ Scopus

    BackgroundDedifferentiated liposarcoma (DDLPS) is one of the most common types of soft tissue sarcoma (STS) characterized by liposarcomatous differentiation and a predilection for the retroperitoneum. Despite the growing number of histology-specific immune checkpoint blockade (ICB) trials in STS…

  11. Journal Article

    The immune landscape of undifferentiated pleomorphic sarcoma

    Rossana Lazcano; Carmelia M. Barreto; Ruth Salazar et al.

    Frontiers in Oncology, Vol. 12 · 2022 · English · DOAJ Scopus

    IntroductionUndifferentiated pleomorphic sarcoma (UPS) can be associated with a relatively dense immune infiltration. Immune checkpoint inhibitors (anti-PD1, anti-PDL1, and anti-CTLA4) are effective in 20% of UPS patients. We characterize the immune microenvironment of UPS and its association with…